Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression

Oncogene

Volumn 28, Issue 45, 2009, Pages 3971-3982

  Kaulfuss S ^a   Von Hardenberg, S ^a   Schweyer, S ^a   Herr, A M ^a   Laccone, F ^b   Wolf, S ^a   Burfeind, P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Leupaxin; P120CTN mediated pathways; Prostate cancer progression

Indexed keywords

BETA CATENIN; CELL ADHESION MOLECULE; LEUPAXIN; MATRILYSIN; PROTEIN P120CATENIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISTANT METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CATENINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION;

MUS; MUS MUSCULUS;

EID: 70449640172     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.254     Document Type: Article

References (47)

1. Anastasiadis PZ. (2006). p120-ctn: a nexus for contextual signaling via Rho GTPases. Biochim Biophys Acta 1773: 34-46.
2. Becker-Hapak M, McAllister SS, Dowdy SF. (2001). TAT-mediated protein transduction into mammalian cells. Methods 24: 247-256.
3. Bidard FC, Pierga JY, Vincent-Salomon A, Poupon MF. (2008). A 'class action' against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev 27: 5-10.
4. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. (1999). Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155: 1033-1038.
5. Brown MC, Turner CE. (2004). Paxillin: adapting to change. Physiol Rev 84: 1315-1339.
6. Chambers AF, Matrisian LM. (1997). Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270.
7. Deakin NO, Bass MD, Warwood S, Schoelermann J, Mostafavi-Pour Z, Knight D et al. (2009). An integrin-{alpha}4-14-3-3{zeta}-paxillin ternary complex mediat. J Cell Sci 15: 1654-1664.
8. Ellerbroek SM, Stack MS. (1999). Membrane associated matrix metalloproteinases in metastasis. Bioessays 21: 940-949.
9. Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T. (2005). Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 4: 1522-1539.
10. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A et al. (1999). Cloning and characterization of androgen receptor coacti-vator, ARA55, in human prostate. J Biol Chem 19: 8316-8321.
11. Gimona M, Buccione R, Courtneidge SA, Linder S. (2008). Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol 20: 235-241.
12. Greenberg NM, DeMayo FJ, Finegold M, Medina D, Tilley W, Aspinall JO et al. (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443.
13. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. (2001). Cancer statistics. CA Cancer J Clin 51: 15-36.
14. Grzmil M, Thelen P, Hemmerlein B, Schweyer S, Voigt S, Mury D et al. (2003). Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol 163: 543-552.
15. Gupta A, Lee BS, Khadeer MA, Tang Z, Chellaiah M, Abu-Amer Y et al. (2003). Leupaxin is a critical adapter protein in the adhesion zone of the osteoclast. J Bone Miner Res 8: 669-685.
16. Gupta GP, Massague J. (2006). Cancer metastasis: building a framework. Cell 127: 679-695.
17. Hatzfeld M. (2005). The p120 family of cell adhesion molecules. Eur J Cell Biol 84: 205-214.
18. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. (2006). Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 231: 20-27.
19. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY et al. (2008). Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 68: 132-142.
20. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. (2005). Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 23: 402-406.
21. Jones LE, Humphreys MJ, Cambell F, Neoptolemos JP, Boyd MT. (2004). Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10: 2832-2845.
22. Kallakury BV, Sheehan CE, Ross JS. (2001a). Co-downregulation of cell adhesion proteins alpha-and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 32: 849-855.
23. Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP et al. (2001b). Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92: 2786-2795.
24. Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, DeFranco DB. (2003). The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res 15: 4927-4935.
25. Kaulfuss S, Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Neesen J et al. (2008). Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Mol Endocrinol 22: 1606-1621.
26. Lauffenburger DA, Horwitz AF. (1996). Cell migration: a physically integrated molecular process. Cell 9: 359-369.
27. Lipsky BP, Beals CR, Staunton DE. (1998). Leupaxin is a novel LIM domain protein that forms a complex with PYK2. J Biol Chem 8: 11709-11713.
28. Liu S, Kiosses WB, Rose DM, Slepak M, Salgia R, Griffin JD et al. (2002). A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem 277: 20887-20894.
29. McDonnell S, Narve M, Coffey Jr RJ, Matrisian LM. (1991). Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4: 527-533.
30. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA et al. (2008). Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26: 5936-5942.
31. Nong CZ, Pan LL, He WS, Zha XL, Ye HH, Huang HY. (2006). P120ctn overexpression enhances beta-catenin-E-cadherin binding and down regulates expression of survivin and cyclin D1 in BEL-7404 hepatoma cells. World J Gastroenterol 28: 1187-1191.
32. Peifer M, Berg S, Reynolds AB. (1994). A repeating amino acid motif shared by proteins with diverse cellular roles. Cell 76: 789-791.
33. Perez-Moreno M, Fuchs E. (2006). Catenins: keeping cells from getting their signals crossed. Dev Cell 11: 601-612.
34. Reynolds AB, Carnahan RH. (2004). Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer. Semin Cell Dev Biol 15: 657-663.
35. Reynolds AB, Daniel J, McCrea PD, Wheelock MJ, Wu J, Zhang Z. (1994). Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol 14: 8333-8342.
36. Rowe RG, Weiss SJ. (2008). Breaching the basement membrane: who, when and how? Trends Cell Biol 18: 560-574.
37. Sahu SN, Khadeer MA, Robertson BW, Nunez S, Bai G, Gupta A. (2007). Association of Leupaxin with Src in osteoclasts. Am J Physiol Cell Physiol 292: C581-C590.
38. Shibanuma M, Kim-Kaneyama JR, Ishino K, Sakamoto N, Hishiki T, Yamaguchi K et al. (2003). Hic-5 communicates between focal adhesions and the nucleus through oxidant-sensitive nuclear export signal. Mol Biol Cell 14: 1158-1171.
39. Shibanuma M, Kim-Kaneyama JR, Sato S, Nose K. (2004). A LIM protein, Hic-5, functions as a potential coactivator for Sp1. J Cell Biochem 91: 633-645.
40. Shiomi T, Okada Y. (2003). MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22: 145-152.
41. Stetler-Stevenson WG. (2001). The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10: 383-392.
42. van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF et al. (2007). The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 67: 1432-1438.
43. Wang H, Song K, Krebs TL, Yang J, Danielpour D. (2008). Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 27: 6791-6805.
44. Wang H, Song K, Sponseller TL, Danielpour D. (2005). Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 280: 5154-5162.
45. Wegener KL, Campbell ID. (2008). Transmembrane and cytoplasmic domains in integrin activation and protein-protein interactions. Mol Membr Biol 25: 376-387.
46. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. (2008). Alterations in beta-catenin expression and localization in prostate cancer. Prostate 68: 1196-1205.
47. Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR. (2000). Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell 11: 2007-2018